Van Lanschot Kempen NV (AMS:VLK)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 2.78B +15.1% |
| Revenue (ttm) | 763.24M +5.1% |
| Net Income | 148.43M +11.0% |
| EPS | 3.47 +11.9% |
| Shares Out | 42.49M |
| PE Ratio | 18.85 |
| Forward PE | 15.25 |
| Dividend | 3.80 (5.81%) |
| Ex-Dividend Date | Jun 23, 2026 |
| Volume | 23,514 |
| Open | 65.40 |
| Previous Close | 65.40 |
| Day's Range | 65.15 - 65.55 |
| 52-Week Range | 48.45 - 67.70 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 65.53 (+0.35%) |
| Earnings Date | Aug 27, 2026 |
About Van Lanschot Kempen NV
Van Lanschot Kempen NV provides various financial services in the Netherlands, Belgium, and internationally. It operates through four segments: Private Clients Netherlands, Private Clients Belgium, Investment Management Clients, and Investment Banking Clients. The company offers private banking services for entrepreneurs, family businesses, high-net-worth individuals, business professionals and executives, foundations and associations, and affluent individuals; and pension funds. It also provides wealth management services and products, an onli... [Read more]
Financial Performance
In 2025, Van Lanschot Kempen NV's revenue was 763.24 million, an increase of 5.12% compared to the previous year's 726.04 million. Earnings were 148.43 million, an increase of 12.57%.
Financial StatementsNews
Van Lanschot Kempen NV Earnings release: Q1 2026
Van Lanschot Kempen NV released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Van Lanschot Kempen NV Slides: Investor presentation
Van Lanschot Kempen NV has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2026.
Van Lanschot Kempen NV Earnings Call Transcript: Q4 2025
Delivered robust 2025 results with 11% net profit growth, 7% AUM increase, and strong commission income, supported by scalable growth, digitalization, and AI initiatives. Proposed EUR 3 dividend and EUR 0.80 capital return, maintaining a solid CET1 ratio.
Van Lanschot Kempen NV Earnings release: Q4 2025
Van Lanschot Kempen NV released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Van Lanschot Kempen NV Slides: Q4 2025
Van Lanschot Kempen NV has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Van Lanschot Kempen NV Earnings release: Q3 2025
Van Lanschot Kempen NV released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
A market correction? We're in stage 3 out of 5, strategist says
Are we on track for a market correction? Joost Van Leenders from Van Lanschot Kempen addresses the latest concerns raised by the IMF and the BOE over high AI-related valuations.
IMF and Bank of England warnings of an AI bubble fits a pattern, strategist says
Joost van Leenders, senior investment strategist at Dutch asset manager Van Lanschot Kempen, discusses the prospect of an artificial intelligence bubble, and the potential ramifications for global sto...
Van Lanschot Kempen NV Earnings Call Transcript: H1 2025
Strong net inflows drove AUM above EUR 150 billion despite negative market performance and lower interest income. Segment results were mixed, with Belgium and investment banking showing strong profit growth, while investment management faced outflows and margin pressure.
Van Lanschot Kempen NV Quarterly report: H1 2025
Van Lanschot Kempen NV has published its H1 2025 quarterly earnings report on August 28, 2025.
Van Lanschot Kempen NV Slides: H1 2025
Van Lanschot Kempen NV has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 28, 2025.
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to add...